Arthur Santora MD

Diabetes, Lipid Metabolism, Osteoporosis & Bone Metabolism Medicine, Parathyroid

Clinical Associate Professor

125 Paterson StClinical Academic Building - Suite 5200aNew Brunswick, NJ 08901
Phone+1 732-235-7219

Dr. Santora is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Santora's full profile Already have an account?

Summary

Dr. Arthur Santora is an endocrinologist based in New Brunswick, NJ, with subspecialties in diabetes, lipid metabolism, osteoporosis, bone metabolism medicine, and parathyroid conditions. He graduated from Emory University School of Medicine in 1978 and completed his residency and fellowship there and at the National Institutes of Health Clinical Center. His career includes roles as a consultant at Kinexum LLC, Chief Medical Officer at EnteraBio LTD, and Associate VP for Clinical Research at Merck, among others. Experienced in managing conditions like hypocalcemia, hypercalcemia, and osteoporosis, he is also published in notable journals, contributing to studies on PTH(1-34) tablets and osteoporosis treatments. His work has been cited multiple times across various publications. Dr. Santora holds certifications from GE Healthcare and the Centers for Medicare & Medicaid Services and is a Fellow of the American Association of Clinical Endocrinology.

Education & Training

National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1981 - 1984
Emory University School of MedicineResidency, Internal Medicine, 1978 - 1981
Emory University School of MedicineClass of 1978

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NJ State Medical License 1989 - 2027
MI State Medical License 1986 - 2020
GA State Medical License 1980 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Centricity EMR, GE Healthcare, 2012-2016
CMS Meaningful Use Stage 1 Certification Centricity EMR, GE Healthcare, 2012-2016
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Publications & Presentations

PubMed

9 citations
Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study.
Liana Tripto-Shkolnik, Auryan Szalat, Gloria Tsvetov, Vanessa Rouach, Chana Sternberg
Journal of Bone and Mineral Research. 2024-07-23
17 citations
Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial
Socrates E. Papapoulos, Henry G. Bone, Felicia Cosman, David W. Dempster, Michael R. McClung
Journal of Bone and Mineral Research. 2021-04-27
3 citations
Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis
Kenneth G. Saag, Felicia Cosman, T. J. de Villiers, Bente L. Langdahl, Boyd B. Scott
Osteoporosis International. 2021-02-19

Journal Articles

Open-Label Study of Treatment with Alendronate Sodium plus Vitamin D in Men and Women with Osteoporosis in Thailand
Arthur Santora, MD, BioMed Central

Press Mentions

Chutes & Ladders—Curis Moves up COO as CEO Fattaey DepartsSeptember 28th, 2018
Former Merck Clinical Research VP Arthur Santora Joins Entera Bio as CMOSeptember 24th, 2018
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenMarch 18th, 2004